Search
Pulmonary Fibrosis Paid Clinical Trials in Texas
A listing of 17 Pulmonary Fibrosis clinical trials in Texas actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 17 of 17
The state of Texas currently has 17 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Join a clinical trial today and take a step toward finding a better solution for you. Earn money for your time and no-cost medical treatment is provided.
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: Baylor University Medical Center, Dallas, Texas +7 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/29/2024
Locations: Baylor Scott & White Research Institute, Dallas, Texas +2 locations
Conditions: Idiopathic Pulmonary Fibrosis
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Recruiting
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: University of Texas Health Science Center at Houston, Houston, Texas +1 locations
Conditions: Pulmonary Fibrosis, COVID-19, Long COVID, Post-acute Respiratory Complications of COVID-19
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas, Dallas, Texas +2 locations
Conditions: Idiopathic Pulmonary Fibrosis
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Recruiting
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date.
Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity.
The experimental therapy here (therapeutic plasma exchange plus... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
08/04/2023
Locations: Baylor University Medical Center, Houston, Texas
Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form
13 - 17 of 17